Patients with heart failure who ask whether surgery is possible often receive an answer that is technically accurate but clinically incomplete. The answer is frequently framed around risk, which is real and worth knowing, without fully accounting for what benefits surgery might offer against that risk. The result is that a meaningful number of patients with heart failure never have a surgical consultation, not because surgery was genuinely ruled out, but because the conversation that would have determined that never took place.

This article maps the surgical landscape for patients with heart failure. It describes what options exist, how risk is assessed in this population, and why the picture is more nuanced than a general statement about elevated surgical risk.

What Heart Failure Means Surgically

Heart failure is a clinical syndrome (a collection of symptoms and signs rather than a single disease) in which the heart cannot pump enough blood to meet the body's needs. The term covers a wide range of conditions. Some patients have heart failure with reduced ejection fraction (HFrEF), meaning the left ventricle (the main pumping chamber of the heart) contracts weakly and pumps out a smaller-than-normal proportion of its blood volume with each beat. Others have heart failure with preserved ejection fraction (HFpEF), meaning the ventricle pumps an apparently normal fraction but is stiff and fills poorly with poor adaptability to volume and diastolic dysfunction .

The ejection fraction (EF) is the percentage of blood in the left ventricle that is pumped out with each heartbeat. A normal EF is 55 to 70 percent. An EF below 40 percent is classified as reduced, and it is in this range that most of the surgical considerations described below become clinically relevant.

Heart failure is not a fixed state. It exists on a spectrum, and its severity, its cause, and its reversibility all determine what surgical options apply and what outcomes are realistic. The first clinical question an open heart surgery specialist in California asks when evaluating a heart failure patient for surgery is not simply "can this patient survive the operation." It is "what caused the heart to fail, and can this cause be addressed by means of Surgical intervention?."

The Connection Between Coronary Artery Disease and Heart Failure

A significant proportion of patients with reduced ejection fraction have coronary artery disease (CAD, the narrowing or blockage of the arteries that supply the heart muscle itself) as the underlying cause of their heart failure. When heart muscle is deprived of blood flow over time, it can become dysfunctional in two distinct ways.

Necrotic myocardium is heart muscle that has been permanently damaged, typically from a heart attack. This tissue does not recover, regardless of intervention and usually becomes scar tissue that is non-functional other than to serve as a focus of abnormal ventricular electrical conduction and to promote clot formation due to the inert nature of the tissue(intramural thrombus).

Hibernating myocardium is heart muscle that is chronically under-perfused (receiving inadequate blood flow) and has reduced its metabolic activity to survive, but retains the capacity to recover function if blood flow is restored. This distinction is clinically important, because it means that a patient whose EF looks severely reduced on an echocardiogram may have a meaningful amount of viable, recoverable heart muscle that is simply not functioning because it is not receiving adequate circulation and energy soiurces.

Imaging studies including dobutamine stress echocardiography (an ultrasound of the heart performed while the patient receives a medication that stimulates the heart, used to identify areas of muscle that respond to increased blood flow and therefore remain viable) and cardiac MRI with gadolinium enhancement (a magnetic resonance imaging technique that identifies scar tissue versus viable muscle) are used to distinguish hibernating from necrotic myocardium.

When a significant portion of dysfunctional heart muscle is found to be hibernating rather than scarred, surgical revascularization (creating new blood flow routes through bypass grafting) can produce recovery of function and increased long term survival that medication alone cannot achieve. The STICH trial (Surgical Treatment for Ischemic Heart Failure, a large randomized controlled trial published in 2011 and with extended follow-up data published in 2016 under the name STICHES) demonstrated that in patients with CAD and reduced EF, bypass surgery combined with medical therapy produced better long-term survival than medical therapy alone. This finding remains an important part of how the surgical option for heart failure patients with CAD is understood and communicated.

Valve Disease and the Failing Heart

Mitral valve disease is particularly common in patients with heart failure. The mitral valve (the valve between the upper and lower chambers on the left side of the heart) can become dysfunctional through two different mechanisms in heart failure patients.

Primary mitral regurgitation occurs when the valve itself is diseased. In secondary mitral regurgitation (also called functional mitral regurgitation), the valve leaflets and supporting structures are structurally normal, but the dilation (enlargement) of the failing left ventricle pulls the valve leaflets and subvalvular apparatus(Cordae and papillary muscles)apart decreasing the surface of coaptation of the valve leaflet due mainly to tethering and overstretching of the primary and secondary cords as the distance between the papillary muscle increases and they become further apart from each other so they no longer close fully. Blood leaks backward into the upper chamber(Left Atrium) with each heartbeat, adding volume load to a heart that is already struggling and also causing eventual dilatation of the left atrium (Left upper Chamber) which eventually leads to chronic Atrial fibrillation further dilating the annulus of the Mitral Valve increasing further the distance between the leaflets of the mitral valve and their effective area of coaptation,, worsening the valve leakage.

The surgical management of mitral regurgitation in patients with significantly reduced EF is an area of ongoing clinical study. For patients with primary mitral valve disease causing heart failure, surgical repair or replacement addresses the mechanism directly. For patients with secondary mitral regurgitation in the context of severely reduced EF, the benefit of surgical intervention is more carefully individualized, and the conversation between the cardiac surgeon and the heart failure team is central to the recommendation.Allowing for the recommendation of palliative procedures for patients with advanced heart failure to become available in some instance to improve quality of life one such example of these recommendations is the use of the Mitral clip; a procedure where the leaflets of the mitral valve are brought together by means of a percutaneously placed clip via a large caliber vein such as the femoral vein in the groin, which increases the area of coaptation and effectively reduces the amount of leakage or regurgitation through the valve improving the symptoms in particular dyspnea with physical activity.

Aortic stenosis (narrowing of the aortic valve, the valve through which blood exits the heart to supply the body) produces a different kind of burden on the failing heart. As the valve narrows, the heart must generate increasing pressure to push blood through a smaller opening. Over time, this pressure load can cause the left ventricle to thicken and eventually weaken. When a patient arrives with both severe aortic stenosis and a reduced EF, the question of whether the low EF is a result of the valve disease rather than an independent process is clinically significant. In patients where valve disease is the cause of the heart failure rather than its consequence, replacing the valve sometimes produces recovery of ventricular function that brings the EF back toward normal range after a period of remodeling and recovery. This outcome is not guaranteed, but it occurs often enough that it is part of the consideration in surgical planning.

Ventricular Restoration Procedures

In some patients with heart failure following large anterior heart attacks (heart attacks affecting the front wall of the left ventricle), the left ventricle develops a scar that is so large it changes the shape of the chamber from its normal elliptical form toward a more spherical one. This shape change reduces pumping efficiency and contributes to worsening heart failure. The scarred segment may form a discrete aneurysm (a thinned, ballooned outpouching of the ventricular wall) or a more diffuse area of akinesis (a region that does not contract at all).

Ventricular restoration surgery, also called surgical ventricular reconstruction (SVR) or the Dor procedure (named after the cardiac surgeon Vincent Dor, who developed the technique), addresses this by excluding the non-functional scarred segment and reshaping the ventricle toward its more efficient elliptical geometry. The procedure is typically performed in conjunction with bypass surgery when the patient has concurrent CAD, and sometimes with mitral valve repair when secondary regurgitation is also present.

Patient selection for ventricular restoration is specific. The procedure offers benefit in patients with a clearly delineated, predominantly anterior scar and demonstrably viable muscle in the remaining ventricular segments. Identifying those patients accurately is a function of preoperative imaging assessment.

Mechanical Circulatory Support: The Bridge and Beyond

For patients with severely reduced cardiac function who are not immediately candidates for conventional surgical repair, or who are being evaluated for heart transplantation, mechanical circulatory support devices can play a significant role.

A left ventricular assist device (LVAD) is a mechanical pump implanted inside the chest that helps the left ventricle circulate blood throughout the body. LVADs are used in several clinical contexts. As a bridge to transplant, meaning support for patients on the heart transplant waiting list whose hearts cannot sustain them until a donor organ becomes available. As destination therapy, meaning long-term support for patients who are not transplant candidates. And increasingly, as a bridge to recovery in selected patients whose heart failure has a potentially reversible cause, where mechanical unloading of the ventricle allows some recovery of function over time.

LVAD implantation is a surgical procedure requiring general anesthesia and carries its own set of procedural risks, which are assessed individually. It is a different category of intervention from the corrective surgeries described earlier in this article, but for the right patient it represents a meaningful extension of quality of life and survival that was not available to the previous generation of heart failure patients.

How Surgical Risk Is Assessed Differently in Heart Failure Patients

Standard surgical risk models including the STS risk score (Society of Thoracic Surgeons predicted risk of mortality, a validated tool that estimates operative risk based on patient characteristics and procedure type) do account for reduced EF as a risk factor. A patient with severely reduced EF will carry a higher predicted operative risk than a patient with normal cardiac function undergoing the same procedure.

What risk scores do not capture is the risk of not operating. A patient with severe ischemic heart failure (heart failure caused by inadequate blood supply due to coronary artery disease) who is not referred for surgical evaluation because the STS score is elevated is being assessed on one side of the risk equation only. The risk of progressive heart failure, of declining function, of the eventual impossibility of transplantation candidacy, is part of the full picture.

An experienced cardiovascular surgeon in California who regularly manages heart failure patients understands this asymmetry and incorporates it into the consultation. The question is not only whether surgery is risky. It is whether surgery's risk is proportionate to what it offers against the trajectory of the disease if surgery is not pursued.

Dr. Williams' Experience With High-Complexity Cardiac Surgery in California

Dr. Julio E. Williams has practiced cardiovascular and thoracic surgery in California for 38 years, and high-complexity cardiac cases, including patients with heart failure, reduced ejection fraction, and prior cardiac interventions, are part of his surgical practice at Mercy Medical Center.

His evaluations of heart failure patients for surgical candidacy draw on a full assessment of the underlying cause of cardiac dysfunction, detailed review of viability imaging when relevant, and a collaborative approach with the referring cardiologist and heart failure team. The surgical recommendation that follows reflects both what is technically feasible and what the clinical evidence supports for the patient's specific profile.

As one of the best cardiac surgeons in California and an experienced open heart surgery specialist in California, Dr. Williams approaches complex heart failure cases with the understanding that many of these patients have never had the option of a surgical opinion presented to them clearly. That conversation, when it happens, sometimes changes the course of care in ways that medication management alone cannot.

What to Bring to a Consultation

Patients with heart failure who are seeking a surgical consultation benefit from arriving with specific information organized and available.

The most recent echocardiogram report and images, along with any prior echocardiograms that allow comparison of EF over time, give the surgeon a picture of the trajectory of ventricular function. Catheterization reports showing the coronary anatomy, if available, are directly relevant to the assessment of whether revascularization applies. Cardiac MRI or nuclear viability study results, where these have been performed, are among the most valuable imaging data for surgical planning in this population.

A current medication list, including any recently initiated heart failure medications and the duration of optimal medical therapy (the term used for the full combination of evidence-based heart failure medications taken at target doses), supports accurate risk assessment.

The name and contact information of the referring cardiologist or heart failure specialist allows the surgical team to coordinate directly and ensures that the consultation builds on rather than duplicates what has already been evaluated.

Coming prepared to discuss functional status, meaning what activities are limited by symptoms, how far the patient can walk, and what has changed over the past months, gives the surgeon clinical context that imaging alone does not provide.

Dr. Julio E. Williams is a board-certified thoracic surgeon with over 25 years of experience. Recognized as an open heart surgery specialist in California and one of the best cardiac surgeons in California, his practice at Mercy Medical Center offers comprehensive surgical evaluation for patients with heart failure, reduced ejection fraction, and complex cardiac conditions across the full spectrum of cardiovascular and thoracic surgery in California.